Journal of Clinical Oncology
The Journal of Clinical Oncology (JCO) is a medical journal published 3 times a month (36 issues a year) by the American Society of Clinical Oncology (ASCO), with a 2010 impact factor of 18.970. JCO now accounts for nearly one in 10 of all oncology journal citations. Coden: JCONDN, LCCN: 84008124 and 82002854, (OCoLC)8320014, online issn: 1527-7755 This journal s focus is work that relates to the care of patients with cancer, e.g., clinical oncology. This journal publishes in varying formats. Original research reports are both a communication tool and reports for original research. Review articles can describe work that builds on previous original research, summarize the current state clinical oncology, or can be a point of critical analysis. Opinion is voiced in editorial formats, which include commentary and discuss controversies. There is also a format for perspectives from a person of public notoriety. Special articles are another form of communication besides original research reports, which promulgate guidelines, summaries of consensus, and other scholarly communications. Fundamental research is covered in the "Biology of Neoplasia" section. A few other formats are also
Study identifies possible new acute leukemia marker, treatment target
A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia that has normal-looking chromosomes under the microscope (that is, cytogenetically normal ...
Cancer
May 13, 2013 |
not rated yet |
0
Genetic test helps predict risk of prostate cancer recurrence
(Medical Xpress)—Prostate cancer ranks as the most common internal malignancy diagnosed in men in the United States, but often does not require extensive treatment.
Cancer
May 10, 2013 |
not rated yet |
0
Experimental drug beneficial in NIH trial to treat a rare sarcoma
(Medical Xpress)—Patients with advanced alveolar soft part sarcoma (ASPS), a rare cancer, achieved some control of their disease using an experimental anti-cancer drug called cediranib. The results from ...
Cancer
May 07, 2013 |
not rated yet |
0
Study suggests patients with lung cancer who carry specific HER2 mutations may benefit from certain anti-HER2 treatments
New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced ...
Cancer
Apr 22, 2013 |
not rated yet |
0
Mammograms reveal response to common cancer drug
Researchers at Karolinska Institutet have developed a method for assessing the effect of tamoxifen, a common drug to prevent the relapse of breast cancer. The key lies in monitoring changes in the proportion of dense tissue, ...
Cancer
Apr 22, 2013 |
not rated yet |
0
First genetic factor in prostate cancer prognosis identified
Patients with prostate cancer and hereditary mutations in the BRCA2 gene have a worse prognosis and lower survival rates than do the rest of the patients with the disease. This is the main conclusion to come out of a study ...
Cancer
Apr 09, 2013 |
not rated yet |
0
New brain cancer treatment may be more effective, less toxic
(Medical Xpress)—A Phase 2 clinical trial testing a new protocol for treating a relatively rare form of brain cancer, primary CNS lymphoma, may change the standard of care for this disease, according to ...
Cancer
Apr 09, 2013 |
not rated yet |
0
|
Adding cetuximab to chemotherapy enables patients with advanced colorectal cancer, liver metastasis to undergo surgery
New results from a clinical trial conducted in Shanghai, China, indicate that adding cetuximab (Erbitux) to standard chemotherapy enables some patients with otherwise inoperable liver metastases due to colorectal cancer have ...
Cancer
Apr 08, 2013 |
not rated yet |
0
Alcohol consumption has no impact on breast cancer survival
Although previous research has linked alcohol consumption to an increased risk of developing breast cancer, a new study has found that drinking before and after diagnosis does not impact survival from the disease. In fact, ...
Cancer
Apr 08, 2013 |
not rated yet |
0
Certain breast cancer patients may benefit from combined HER2 targeted therapy without chemotherapy
Is the era of targeted therapy for breast cancer at hand? It could be, said experts at the Lester and Sue Smith Breast Center at Baylor College of Medicine – at least for a certain population of women.
Cancer
Apr 08, 2013 |
not rated yet |
0
Smoking worsens outcomes with advanced colon cancer
(HealthDay)—Smoking is tied to significantly shorter disease-free survival (DFS) and time to recurrence (TTR) in patients undergoing treatment for stage III colon cancer, according to a study published ...
Cancer
Apr 06, 2013 |
5 / 5 (1) |
2
Program linked to medical oncology practice improvement
(HealthDay)—For medical oncology practices in the United States, participation in the American Society of Clinical Oncology's Quality Oncology Practice Initiative (QOPI) correlates with improvements in ...
Cancer
Apr 06, 2013 |
not rated yet |
0
Belgium study tracks trends in end-of-life decision making
(HealthDay)—In Belgium, between 1998 and 2007, euthanasia was legalized and palliative care was intensified, which led to an increase in end-of-life decisions (ELDs) and fewer life-ending acts without the ...
Health
Apr 03, 2013 |
not rated yet |
0
Study tracks patterns of US cases of anal canal carcinoma
(HealthDay)—Available screening and identification of human papillomavirus likely contributed to the increased incidences of squamous cell carcinoma of the anal canal (SCCA) and anal carcinoma in situ (CIS) ...
Cancer
Apr 02, 2013 |
5 / 5 (2) |
0
Prostate cancer risk rises in men with inherited genetic condition
Men with an inherited genetic condition called Lynch syndrome face a higher lifetime risk of developing prostate cancer and appear to develop the disease at an earlier age, according to a new study led by ...
Cancer
Apr 01, 2013 |
not rated yet |
0
|
